Premium Essay

Genzyme Csr Dilemma

In: Business and Management

Submitted By mdamatta
Words 2383
Pages 10
EMBA Winter 2016

SMO 860: Management of Technology and Innovation

April ,07,2016

Case Analysis: Genzyme’s CSR Dilemma: How to Play Its HAND

Marcio Augusto da Matta augustod@ualberta.ca Dr. Anthony R. Briggs
-------------------------------------------------

1. Introduction
Genzyme is a biotechnology company with a leading role in the world’s treatment for Orphan and neglected diseases. At the moment its Senior VP, Mr. Geragthy faces a time for decisions. The analysis momentum is over and he must propose the best direction for the company. I will go deeply inside the company and analyse the inside and outside scenario to be able to run the VRIO model and give my preference to Mr. Geragthy. 2. Genzyme’s history
All started with the supply of enzymes, fine chemicals and reagents to research and pharmaceutical companies. Its founder, Mr. Henry Blair since the beginning had a vision to become a world leader and always focused by identifying patient’s needs, targeting a focused technology capability, and developing a set of values that clearly defined its role as a corporation society.
Since the beginning the strategy was on orphaned diseases and it reflected in its portfolio of drugs and achieving the leadership with revenues of almost $4 billion in 2007.
In 1983 Mr. Blair felt the need for help and brought on board Mr. Henri Termeer who had a very important role on the company’s development and together they have taken the company public and launched the orphan drug application for the enzyme that turned to be a turn around point for Genzyme.
Since the beginning Mr. Termeer saw the importance of R & D to build a diversified pipeline of products.

3. The Corporate Social Responsibility importance
Genzyme decided to take a radically different approach to the business due its patient focused culture and its sense of

Similar Documents

Premium Essay

Genzyme

...Case 8-4: Genzyme’s CSR Dilemma: How to Play its HAND 1. In your opinion, which of the three major HAND initiatives: TB, Malaria, or Chagas should Jim Geraghty recommend? Defend you answer by detailing how your choice is better than the other two. I think that Jim Geraghty should recommend the Malaria initiative. The Malaria initiative is the best business decision for Genzyme. There are 250 million Malaria cases every year, compared to that of 16-18 million cases of Chagas and 25 million cases of Tuberculosis. Even though Tuberculosis has more deaths per year at 1.5-2 million and could possibly be the best initiative to recommend, I still believe the Malaria initiative is the best option. Malaria is spread by Anopheles mosquitos and there is still a great need for a cure of Malaria in today’s world. In the case, Genzyme’s goal is to have the most impact possible on a deadly disease, while doing something that is within their capabilities. All three initiatives have a very important medical need, but Genzyme has the molecular knowledge to create a vaccine for Malaria. They have done a lot of research for Chagas also, but they would have to basically start from scratch if they were to go towards the Tuberculosis initiative. By going with the Malaria initiative, they would more than likely partner with Harvard, MMV, and ICGEB, which would be great for the research and development capabilities. Jim Geraghty should recommend the Malaria initiative to Henri Teermer 2. Taking the...

Words: 664 - Pages: 3

Free Essay

Dddddd

...Chapter 1 expanding abroad: motivations, means, and mentalities Case 1-1 Cameron Auto Parts * Alex Cameron got the family biz when graduated in 2001, when the American economy fell into a recession * History * Auto Pact, big three ship car parts between Canada & US, with tariff free * Cameron focus on small engine parts and auto accessories * Car Sales dropped in 2000, because declining North America and entry of Japanese * High pressure for modernization and cost reduction * Operational survival: cut workforce, overtime, part-time, subcontracting * Recovery and diversification * The short-term future seemed positive, but the popularity of Japanese car forced it to diversify * Working as an OEM Cameron did little to be innovative * Alex brought in a team of designers, concentrating on developing products with a wider ‘non-automotive’ market appeal * The first year no progress, Alex lured away a key engineer from the Canadian firm, and mid-2003, developed its own line of flexible couplings * Marketing the new product * Hired eight field sales representatives, stress product quality, service and speed of delivery, but not price. * Financing plant capacity * Increasing sales of flexible couplings required a new separate plant, but the financial position is not strong enough to support it * Foreign markets * Took a European Patent * A licensing opportunity ...

Words: 18260 - Pages: 74